RAS-MAPK pathway inhibition in Noonan syndrome — the emerging targeted therapy approach addressing the underlying molecular pathophysiology of PTPN11, SOS1, RAF1, and KRAS mutations, representing the most scientifically transformative development in the Noonan Syndrome Market — creates the most clinically anticipated market segment, with MEK inhibitors and SHP2 inhibitors reflecting...